James Investment Research Inc. Invests $210,000 in Artivion, Inc. $AORT

James Investment Research Inc. bought a new position in shares of Artivion, Inc. (NYSE:AORT) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,753 shares of the company’s stock, valued at approximately $210,000.

Other hedge funds have also modified their holdings of the company. MCF Advisors LLC boosted its stake in shares of Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after acquiring an additional 614 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Artivion during the 1st quarter worth about $284,000. Natixis Advisors LLC boosted its stake in shares of Artivion by 16.4% during the 1st quarter. Natixis Advisors LLC now owns 12,615 shares of the company’s stock worth $310,000 after acquiring an additional 1,777 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Artivion by 18.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company’s stock worth $353,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Diker Management LLC acquired a new position in shares of Artivion during the 1st quarter worth about $369,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Oppenheimer restated an “outperform” rating on shares of Artivion in a research report on Friday, August 8th. JMP Securities upped their price target on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Citigroup restated an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. Needham & Company LLC upped their price target on shares of Artivion from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, August 22nd. Finally, LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and upped their price target for the stock from $32.00 to $38.80 in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.97.

Artivion Stock Up 1.2%

AORT stock opened at $45.27 on Wednesday. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -107.78 and a beta of 1.67. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.79. The firm has a 50-day moving average of $42.11 and a two-hundred day moving average of $34.21.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company’s revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity

In other news, insider John E. Davis sold 10,802 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the sale, the insider owned 208,778 shares in the company, valued at $9,117,335.26. This trade represents a 4.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James P. Mackin sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the sale, the chief executive officer owned 852,783 shares of the company’s stock, valued at $36,089,776.56. This represents a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 74,858 shares of company stock worth $3,250,129 over the last quarter. 8.10% of the stock is currently owned by corporate insiders.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.